{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:42:14Z","timestamp":1790995334990,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10549-026-07903-x","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T06:03:49Z","timestamp":1770185029000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exercise training decreases Neuregulin-1 concentrations in HER2-positive breast cancer patients undergoing adjuvant trastuzumab: the CARDAPAC study"],"prefix":"10.1007","volume":"215","author":[{"given":"Quentin","family":"Jacquinot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebl","family":"Ennequin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Falcoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Meneveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Mougin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"7903_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"7903_CR2","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/1055-9965.EPI-18-0098","volume":"27","author":"RM Pfeiffer","year":"2018","unstructured":"Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH (2018) Proportion of U.S. trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev 27:1214\u20131222. https:\/\/doi.org\/10.1158\/1055-9965.EPI-18-0098","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"7903_CR3","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/1055-9965.EPI-20-1193","volume":"30","author":"SC Houghton","year":"2021","unstructured":"Houghton SC, Hankinson SE (2021) Cancer progress and priorities: breast cancer. Cancer Epidemiol Biomarkers Prev 30:822\u2013844. https:\/\/doi.org\/10.1158\/1055-9965.EPI-20-1193","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"7903_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.5301\/ijbm.5000262","volume":"32","author":"F De luliis","year":"2017","unstructured":"De luliis F, Salerno G, Taglieri L, Lanza R, Cardelli P, Scarpa S (2017) Circulating neuregulin-1 and galectin-3 can be prognostic markers in breast cancer. Int J Biol Markers 32:333\u2013336. https:\/\/doi.org\/10.5301\/ijbm.5000262","journal-title":"Int J Biol Markers"},{"key":"7903_CR5","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E et al (2017) 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial. Lancet 389:1195\u20131205. https:\/\/doi.org\/10.1016\/S0140-6736(16)32616-2","journal-title":"Lancet"},{"key":"7903_CR6","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","volume":"32","author":"EA Perez","year":"2014","unstructured":"Perez EA, Romond EH, Suman VJ, Jeong J-H, Sledge G, Geyer CE et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32:3744\u20133752. https:\/\/doi.org\/10.1200\/JCO.2014.55.5730","journal-title":"J Clin Oncol"},{"key":"7903_CR7","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1200\/JCO.2015.64.5515","volume":"34","author":"CT Dang","year":"2016","unstructured":"Dang CT, Yu AF, Jones LW, Liu J, Steingart RM, Argolo DF et al (2016) Cardiac surveillance guidelines for trastuzumab-containing therapy in early-stage breast cancer: getting to the heart of the matter. J Clin Oncol 34:1030\u20131033. https:\/\/doi.org\/10.1200\/JCO.2015.64.5515","journal-title":"J Clin Oncol"},{"key":"7903_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","volume":"102","author":"A Albini","year":"2010","unstructured":"Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. JNCI J Natl Cancer Inst 102:14\u201325. https:\/\/doi.org\/10.1093\/jnci\/djp440","journal-title":"JNCI J Natl Cancer Inst"},{"key":"7903_CR9","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1161\/CIRCRESAHA.112.267286","volume":"111","author":"O Odiete","year":"2012","unstructured":"Odiete O, Hill MF, Sawyer DB (2012) Neuregulin in cardiovascular development and disease. Circ Res 111:1376\u20131385. https:\/\/doi.org\/10.1161\/CIRCRESAHA.112.267286","journal-title":"Circ Res"},{"key":"7903_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1161\/CIRCRESAHA.118.312669","volume":"124","author":"CJ Lavie","year":"2019","unstructured":"Lavie CJ, Ozemek C, Carbone S, Katzmarzyk PT, Blair SN (2019) Sedentary behavior, exercise, and cardiovascular health. Circ Res 124:799\u2013815. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.312669","journal-title":"Circ Res"},{"key":"7903_CR11","doi-asserted-by":"publisher","DOI":"10.1159\/000535737","author":"C-H Chiang","year":"2023","unstructured":"Chiang C-H, Chang Y-C, Haw Y, Tan JY, Chiang C-H, Hsia YP (2023) The effect of exercise on cardiotoxicity in women with breast cancer receiving anthracycline-based chemotherapy: a systematic review and meta-analysis. Oncology. https:\/\/doi.org\/10.1159\/000535737","journal-title":"Oncology"},{"key":"7903_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-024-00208-2","volume":"10","author":"AM Amin","year":"2024","unstructured":"Amin AM, Khlidj Y, Abuelazm M, Ibrahim AA, Tanashat M, Imran M et al (2024) The efficacy and safety of exercise regimens to mitigate chemotherapy cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials. Cardio-Oncol 10:10. https:\/\/doi.org\/10.1186\/s40959-024-00208-2","journal-title":"Cardio-Oncol"},{"key":"7903_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-023-00172-3","volume":"9","author":"H Eaton","year":"2023","unstructured":"Eaton H, Timm KN (2023) Mechanisms of trastuzumab induced cardiotoxicity \u2013 is exercise a potential treatment? Cardio-Oncol 9:22. https:\/\/doi.org\/10.1186\/s40959-023-00172-3","journal-title":"Cardio-Oncol"},{"key":"7903_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1000846","author":"Q Jacquinot","year":"2022","unstructured":"Jacquinot Q, Meneveau N, Falcoz A, Bouhaddi M, Roux P, Degano B et al (2022) Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumab. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2022.1000846","journal-title":"Front Cardiovasc Med"},{"key":"7903_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3420-4","volume":"17","author":"Q Jacquinot","year":"2017","unstructured":"Jacquinot Q, Meneveau N, Chatot M, Bonnetain F, Degano B, Bouhaddi M et al (2017) A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study. BMC Cancer 17:1\u201311. https:\/\/doi.org\/10.1186\/s12885-017-3420-4","journal-title":"BMC Cancer"},{"key":"7903_CR16","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.echo.2004.07.013","volume":"17","author":"JS Gottdiener","year":"2004","unstructured":"Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ et al (2004) American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 17:1086\u20131119. https:\/\/doi.org\/10.1016\/j.echo.2004.07.013","journal-title":"J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr"},{"key":"7903_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 28:1-39.e14. https:\/\/doi.org\/10.1016\/j.echo.2014.10.003","journal-title":"J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr"},{"key":"7903_CR18","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"key":"7903_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3420-4","volume":"17","author":"Q Jacquinot","year":"2017","unstructured":"Jacquinot Q, Meneveau N, Chatot M, Bonnetain F, Degano B, Bouhaddi M et al (2017) A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study. BMC Cancer 17:425. https:\/\/doi.org\/10.1186\/s12885-017-3420-4","journal-title":"BMC Cancer"},{"key":"7903_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/BF00441298","volume":"49","author":"M Gimenez","year":"1982","unstructured":"Gimenez M, Servera E, Saunier C, Lacoste J (1982) Square-wave endurance exercise test (SWEET) for training and assessment in trained and untrained subjects. Eur J Appl Physiol 49:369\u2013377. https:\/\/doi.org\/10.1007\/BF00441298","journal-title":"Eur J Appl Physiol"},{"key":"7903_CR21","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1158\/1078-0432.CCR-07-5133","volume":"14","author":"JC Montero","year":"2008","unstructured":"Montero JC, Rodr\u00edguez-Barrueco R, Oca\u00f1a A, D\u00edaz-Rodr\u00edguez E, Espar\u00eds-Ogando A, Pandiella A (2008) Neuregulins and cancer. Clin Cancer Res Off J Am Assoc Cancer Res 14:3237\u20133241. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-5133","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"7903_CR22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.20996\/1819-6446-2021-11-01","volume":"17","author":"KA Zhbanov","year":"2022","unstructured":"Zhbanov KA, Shchendrygina AA, Zheleznykh EA, Privalova EV, Suvorov AY, Ablyametova AS et al (2022) Plasma level\u2019s of neuregulin-1 in healthy people. Ration Pharmacother Cardiol 17:853\u2013859. https:\/\/doi.org\/10.20996\/1819-6446-2021-11-01","journal-title":"Ration Pharmacother Cardiol"},{"key":"7903_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.cardfail.2012.11.006","volume":"19","author":"CA Geisberg","year":"2013","unstructured":"Geisberg CA, Abdallah WM, Da Silva M, Silverstein C, Smith HM, Abramson V et al (2013) Circulating neuregulin during the transition from stage A to stage B\/C heart failure in a breast cancer cohort. J Card Fail 19:10\u201315. https:\/\/doi.org\/10.1016\/j.cardfail.2012.11.006","journal-title":"J Card Fail"},{"key":"7903_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.109.856310","volume":"120","author":"B Ky","year":"2009","unstructured":"Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC et al (2009) Neuregulin-1\u03b2 is associated with disease severity and adverse outcomes in chronic heart failure. Circulation 120:310\u2013317. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.856310","journal-title":"Circulation"},{"key":"7903_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2016.04.012","volume":"97","author":"K-A Chang","year":"2016","unstructured":"Chang K-A, Shin KY, Nam E, Lee Y-B, Moon C, Suh Y-H et al (2016) Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer\u2019s disease. Neurochem Int 97:1\u20137. https:\/\/doi.org\/10.1016\/j.neuint.2016.04.012","journal-title":"Neurochem Int"},{"key":"7903_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1615\/JEnvironPatholToxicolOncol.2021039839","volume":"40","author":"C Fang","year":"2021","unstructured":"Fang C, Kang B, Zhao P, Ran J, Wang L, Zhao L et al (2021) Targeting Neuregulin 1 (NRG1): a novel biomarker for non-small-cell lung cancer. J Environ Pathol Toxicol Oncol 40:61\u201372. https:\/\/doi.org\/10.1615\/JEnvironPatholToxicolOncol.2021039839","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"7903_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.breast.2021.12.001","volume":"61","author":"MJ Heins","year":"2022","unstructured":"Heins MJ, de Ligt KM, Verloop J, Siesling S, Korevaar JC, PSCCR group (2022) Adverse health effects after breast cancer up to 14 years after diagnosis. Breast 61:22\u201328. https:\/\/doi.org\/10.1016\/j.breast.2021.12.001","journal-title":"Breast"},{"key":"7903_CR28","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.canrad.2020.12.005","volume":"25","author":"B Vandendorpe","year":"2021","unstructured":"Vandendorpe B, Drouet Y, Ramiandrisoa F, Guilbert P, Costa B, Servagi-Vernat S (2021) Psychological and physical impact in women treated for breast cancer: need for multidisciplinary surveillance and care provision. Cancer Radiother 25:330\u2013339. https:\/\/doi.org\/10.1016\/j.canrad.2020.12.005","journal-title":"Cancer Radiother"},{"key":"7903_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2702.2006.01638.x","volume":"16","author":"MN Kirshbaum","year":"2007","unstructured":"Kirshbaum MN (2007) A review of the benefits of whole body exercise during and after treatment for breast cancer. J Clin Nurs 16:104\u2013121. https:\/\/doi.org\/10.1111\/j.1365-2702.2006.01638.x","journal-title":"J Clin Nurs"},{"key":"7903_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2024.107932","volume":"183","author":"A Fern\u00e1ndez-Casas","year":"2024","unstructured":"Fern\u00e1ndez-Casas A, Leir\u00f3s-Rodr\u00edguez R, Hernandez-Lucas P, Gonz\u00e1lez-Represas A (2024) Protective effects of exercise on cardiotoxicity induced by breast cancer treatments: a systematic review and meta-analysis. Maturitas 183:107932. https:\/\/doi.org\/10.1016\/j.maturitas.2024.107932","journal-title":"Maturitas"},{"key":"7903_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1875318300902010001","volume":"2","author":"V Moondra","year":"2009","unstructured":"Moondra V, Sarma S, Buxton T, Safa R, Cote G, Storer T et al (2009) Serum Neuregulin-1\u03b2 as a biomarker of cardiovascular fitness. Open Biomark J 2:1\u20135. https:\/\/doi.org\/10.2174\/1875318300902010001","journal-title":"Open Biomark J"},{"key":"7903_CR32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/ehf2.12615","volume":"7","author":"C Hage","year":"2020","unstructured":"Hage C, W\u00e4rdell E, Linde C, Donal E, Lam CSP, Daubert C et al (2020) Circulating neuregulin1\u2010\u03b2 in heart failure with preserved and reduced left ventricular ejection fraction. ESC Heart Fail 7:445\u2013455. https:\/\/doi.org\/10.1002\/ehf2.12615","journal-title":"ESC Heart Fail"},{"key":"7903_CR33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00421-005-1333-4","volume":"94","author":"NK LeBrasseur","year":"2005","unstructured":"LeBrasseur NK, Mizer KC, Parkington JD, Sawyer DB, Fielding RA (2005) The expression of neuregulin and erbB receptors in human skeletal muscle: effects of progressive resistance training. Eur J Appl Physiol 94:371\u2013375. https:\/\/doi.org\/10.1007\/s00421-005-1333-4","journal-title":"Eur J Appl Physiol"},{"key":"7903_CR34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3109\/09553002.2013.782110","volume":"89","author":"V Sridharan","year":"2013","unstructured":"Sridharan V, Sharma SK, Moros EG, Corry PM, Tripathi P, Lieblong BJ et al (2013) Effects of radiation on the epidermal growth factor receptor pathway in the heart. Int J Radiat Biol 89:539\u2013547. https:\/\/doi.org\/10.3109\/09553002.2013.782110","journal-title":"Int J Radiat Biol"},{"key":"7903_CR35","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S1470-2045(05)70251-5","volume":"6","author":"SC Darby","year":"2005","unstructured":"Darby SC, McGale P, Taylor CW, Peto R (2005) Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 6:557\u2013565. https:\/\/doi.org\/10.1016\/S1470-2045(05)70251-5","journal-title":"Lancet Oncol"},{"key":"7903_CR36","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4103\/0973-1482.187303","volume":"13","author":"K Rygiel","year":"2017","unstructured":"Rygiel K (2017) Cardiotoxic effects of radiotherapy and strategies to reduce them in patients with breast cancer: an overview. J Cancer Res Ther 13:186. https:\/\/doi.org\/10.4103\/0973-1482.187303","journal-title":"J Cancer Res Ther"},{"key":"7903_CR37","doi-asserted-by":"publisher","first-page":"117634","DOI":"10.1016\/j.lfs.2020.117634","volume":"251","author":"E Boateng","year":"2020","unstructured":"Boateng E, deKay JT, Peterson SM, Boles J, Pinnette N, Sorcher MW et al (2020) High ErbB3 activating activity in human blood is not due to circulating neuregulin-1 beta. Life Sci 251:117634. https:\/\/doi.org\/10.1016\/j.lfs.2020.117634","journal-title":"Life Sci"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07903-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07903-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07903-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T09:29:04Z","timestamp":1770802144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07903-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7903"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07903-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7242299\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the French National Health Products Safety Agency (P\/2014\/241) and this trial was registered on the National Clinical Trials under the number NCT02433067.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"69"}}